Major bleeding risk among non‐valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a “real‐world” observational study in the United States

BACKGROUND: Limited data are available about the real‐world safety of non‐vitamin K antagonist oral anticoagulants (NOACs). OBJECTIVES: To compare the major bleeding risk among newly anticoagulated non‐valvular atrial fibrillation (NVAF) patients initiating apixaban, warfarin, dabigatran or rivaroxa...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Int J Clin Pract
Main Authors: Lip, Gregory Y. H., Pan, Xianying, Kamble, Shital, Kawabata, Hugh, Mardekian, Jack, Masseria, Cristina, Bruno, Amanda, Phatak, Hemant
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2016
Assuntos:
Cardiology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5129572/
https://ncbi.nlm.nih.gov/pubmed/27550177
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ijcp.12863
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados